Bayer clinches $2.9B Algeta deal; Hypermarcas profits dive 56% in Q4 despite higher sales;

@FiercePharma: With Teva's Symbicort copy nearing EU launch, AstraZeneca preps for battle. Story | Follow @FiercePharma

@TracyStaton: Top story at FiercePharma over weekend: FDA moves toward major overhaul in the way it approves OTC meds. More | Follow @TracyStaton

@EricPFierce: GSK could get some financial breathing room with an EU nod for Anoro. Report | Follow @EricPFierce

@CarlyHFierce: Vertex eyes another $45 million in sales as FDA swells Kalydeco's patient pool. News | Follow @CarlyHFierce

> Bayer has snagged a $2.9 billion deal for Norway's Algeta. Report

> Profits for Brazil's Hypermarcas sank 56% in Q4, with higher sales undercut by the financial cost of a weaker currency and repurchases of bonds. More

> Eli Lilly ($LLY) will pick up Germany's Lohmann Animal Health for an undisclosed sum. Report

> Private equity firm TPG plans to take healthcare company Chindex International ($CHDX) private in a $369 million deal, which will make China's Fosun Pharma its largest shareholder. News

> Roche ($RHHBY) has tapped real estate firm Jones Lang LaSalle to sell its campus, which measures approximately 120 acres and encompasses parts of New Jersey towns Nutley and Clifton. Report

> KV Pharmaceuticals has tabbed Gregg Raybuck as president of its new maternal health division, part of a larger restructuring that also created a new women's healthcare division. News

> A Maryland federal judge Friday shut down Par Pharmaceutical's bid to keep its patent for Megace ES, a drug that fights anorexia and extreme weight loss in AIDS patients. More (sub. req.)

Medical Device News

@FierceMedDev: German study backs a Japanese firm's dissolving stent over the bare metal variety. Story | Follow @FierceMedDev

@MichaelGFierce: Capsule Tech launches a medical device integration system with a few big partners. More | Follow @MichaelGFierce

@EmilyWFierce: 3-D printing technology could be used to construct human organs, say scientists. Article | Follow @EmilyWFierce

@GalenMoore: Startup Constant Therapy raises seed funds for its iPad-based brain injury treatment. More | Follow @GalenMoore

> Endo is stocking up at least $520M to cover vaginal mesh lawsuit legal costs. Story

> Boston Scientific partners up to push Parkinson's tech in Europe. Article

Biotech News

@FierceBiotech: Assessing the crowd effect on biopharma's risky R&D strategy. More | Follow @FierceBiotech

@JohnCFierce: Bristol-Myers picks up another "breakthrough" trophy in hep C cocktail showdown. News | Follow @JohnCFierce

@DamianFierce: As Big Pharma sells/spins out its animal health ops, Lilly buys one. Release | Follow @DamianFierce

@EmilyMFierce: Gene therapy regenerates damaged tissue in pigs after heart attack. Story | Follow @EmilyMFierce

> DNAtrix bags $10.8M to advance its cancer-killing virus. Story

> Busy Servier grabs an option on Celladon's early-stage diabetes work. News

CRO News

> Medpace changes hands for $915M as private equity smiles on CROs. News

> After soaring 20% in 2013, Icon eyes a bigger share of the CRO market. Article

> Quintiles lends its sequencing skills to massive cardiovascular study. Story

> Parexel expands its regulatory reach with latest move. News

> PPD partners up to give Germany a starring role in clinical trials. Story

> Charles River amps up its biologics testing. Item

Biotech IT News

> Buzz: BGI is preparing for a $400M Hong Kong IPO in Q4. Report

> U.K. delays patient database project following public backlash. News

> Roche mulls sharing Avastin trial data to clear up possible statistical quirk. Story

> U.S. team taps supercomputer to accelerate genome data analysis. Article

> Merge prepares to defend itself against fake contract lawsuits. News

> Pfizer CEO begins contributing to LinkedIn's publishing platform. Brief

And Finally... Will e-cigarettes help eradicate conventional smoking or serve as a gateway to tobacco use? Story (sub. req.)

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.